Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

BACKGROUND: Pirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of safety data from five clinical trials evaluating pirfenidone in patients with IPF. METHODS: Al...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMJ Open Respir Res
Главные авторы: Lancaster, Lisa, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, du Bois, Roland M, Fagan, Elizabeth A, Fishman, Robert S, Glaspole, Ian, Glassberg, Marilyn K, King, Talmadge E, Lederer, David J, Lin, Zhengning, Nathan, Steven D, Pereira, Carlos A, Swigris, Jeffrey J, Valeyre, Dominique, Noble, Paul W
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2016
Предметы:
Interstitial Lung Disease
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4716177/
https://ncbi.nlm.nih.gov/pubmed/26835133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2015-000105
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы